Overcome Your Clinical & Commercial Challenges to Accelerate the Development of Your Gene Therapy for Blood Disorders to Market

There’s currently a lot of exciting news circulating about the progress of genetic therapies targeting blood disorders.

As more and more promising results emerge from various clinical 3 trials, it’s essential that this industry comes together to share knowledge, optimize trial design and discuss strategies for commercial launch.

The 2nd Gene Therapy for Blood Disorders is the only industry meeting specifically dedicated to overcoming the clinical and commercial challenges faced in gene therapy drug development for hemophilia, sickle cell disease, beta thalassemia and other blood disorders.

Join the likes of UniQure, Graphite Bio, bluebird bio, Sanofi, Spark Therapeutics and more industry pioneers as they share their latest insights and lessons learned to help accelerate programs to market.

Download the event guide here to find out how this meeting will help transform your clinical candidates into a commercial reality.

Previous Gene Therapy for Blood Disorders Attendees said:

“The quality of participants, speakers and presentations were all excellent”

Associate Director, Business Insights, Sanofi

“Well balanced conference covering bench to patient perspectives”

Director, Medical Communication & Educational Strategy, CSL Behring

“Very interesting and well organised agenda covering hot topics in the industry”

Director, Strategy & Business Operations, Freeline Therapeutics

Who Attended in 2021?

 Proud To Partner With:

Other Events in the Gene Therapy Series